Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 05 November 2012 | By Ansis Helmanis,
Brazil's National Health Surveillance Agency (Anvisa) met on 31 October 2012 to discuss the potential impact of nanotechnology on various fields, including medicines and biology, and how the technology could be used to benefit the country's national strategic priorities on public health and industrial development.
The use of nanotechnology has been associated with potential risks to human health, and Anvisa regulators made clear that the agency sees its role as both a facilitator of innovation and a protector of public health.
According to Agenor Álvares, a director at Anvisa, "The [agency] must continually monitor technological advances related to health, and Anvisa … has an important role in implementing these innovations."
Participants at the meeting included the Department of the Secretary of Innovative Technology of the Ministry of Development, the Industry and Foreign Trade Ministry, the Department of Technology Development, and the Oswaldo Cruz Foundation.
Read all Breaking News from RegLink
Tags: nanotechnology, Meeting, Latest News, brazil
Regulatory Focus newsletters
All the biggest regulatory news and happenings.